Document Type : Review Article
Authors
- Tomnah Ali Mohammed Alamodi 1
- Hatem A. M. Saleh 2, 3
- Fahd Mohammed Abdullah Makhsham 4
- Rasha Kadoun 5
- Yong Feng Chen 1
1 Dermatology Hospital, Southern Medical University, Guangzhou, China
2 Aligarh Muslim University, Aligarh, UP, India
3 Department of Chemistry Aden Gulf International University.Aden, Yemen
4 Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, China
5 School of Nursing, Southern Medical University, Guangzhou, China
Abstract
Psoriasis, a chronic inflammatory skin disease, has been increasingly associated with diabetes mellitus (DM), suggesting shared pathophysiological mechanisms between the two conditions. Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, has emerged as a promising treatment option for psoriatic arthritis and psoriasis, and recent studies have explored its potential benefits in patients with diabetes. This review provides a thorough investigation of the current literature on apremilast's mechanism of action, pharmacokinetics, therapeutic potential, and safety in psoriasis management, particularly in patients with diabetes. Studies have shown that apremilast's PDE4 inhibition leads to increased cAMP levels, which may improve metabolic inflammation and insulin resistance. Observational studies have also indicated the potential benefits of apremilast in managing insulin resistance among psoriasis patients. In addition, drug interaction studies have shed light on the effects of co-administering apremilast with other substances, emphasizing the importance of cautious prescribing. In conclusion, apremilast holds promise as a powerful and secure treatment option for psoriasis patients, with potential benefits in managing insulin resistance in patients with diabetes. Further research and larger clinical trials are needed to validate and expand upon these findings, paving the way for more personalized and effective therapeutic approaches.
Graphical Abstract
)
Keywords
Main Subjects
[1]. W.H. Boehncke, M.P. Schön, Psoriasis, Lancet (London, England), 2015, 386, 983-994. [Crossref], [Publisher]
[2]. a) J.G. Holm, S.F. Thomsen, Type 2 diabetes and psoriasis: links and risks, Psoriasis (Auckland, N.Z.), 2019, 9, 1-6. [Google Scholar], [Publisher] b) H. khajeh, A. Bahari, A. Rashki, TCF7L2 polymorphisms in type 2 diabetes, insight from HRM and ARMS techniques, International Journal of Advanced Biological and Biomedical Research, 2021, 9, 204-214. [Crossref], [Google Scholar], [Publisher] c) S. Azizi, R. Behzadi Andohjerdi, H. Mohajerani, Evaluation of two types of vitamin D receptor gene morphism in patients with type 2 diabetes and obesity, International Journal of Advanced Biological and Biomedical Research, 2020, 8, 86-91. [Crossref], [Google Scholar], [Publisher]
[3]. B.J. Shah, D. Mistry, N. Chaudhary, S. Shah, Real-world efficacy and safety of apremilast monotherapy in the management of moderate-to-severe psoriasis, Indian Dermatology Online Journal, 2020, 11, 51-57. [Crossref], [Google Scholar], [Publisher]
[4]. G.M. Keating, Apremilast: A review in psoriasis and psoriatic arthritis, Drugs, 2017, 77, 459-472. [Crossref], [Google Scholar], [Publisher]
[5]. R.M. Poole, A.D. Ballantyne, Apremilast: First global approval, Drugs, 2014, 74, 825-837. [Crossref], [Google Scholar], [Publisher]
[6]. E.D. Deeks, Apremilast: A review in oral ulcers of behçet’s disease, Drugs, 2020, 80, 181-188. [Crossref], [Google Scholar], [Publisher]
[7]. S.L. Haber, S. Hamilton, M. Bank, S.Y. Leong, E. Pierce, Apremilast: A novel drug for treatment of psoriasis and psoriatic arthritis, Annals of Pharmacotherapy, 2016, 50, 282-290. [Crossref], [Google Scholar], [Publisher]
[8]. B. Shutty, C. West, M. Pellerin, S. Feldman, Apremilast as a treatment for psoriasis, 2012, Expert Opinion on Pharmacotherapy, 13, 1761-1770. [Crossref], [Google Scholar], [Publisher]
[9]. M. Rajagopalan, S. Dogra, A. Saraswat, S. Varma, P. Banodkar, The use of apremilast in psoriasis: An indian perspective on real-world scenarios, Psoriasis (Auckland, N.Z.), 2021, 11, 109-122. [Google Scholar], [Publisher]
[10]. M.G. Ivanic, A. Thatiparthi, S. Walia, W. Liao, J.J. Wu, Review of apremilast combination therapies in the treatment of moderate to severe psoriasis, Journal of Drugs in Dermatology: JDD, 2021, 20, 837-843. [Crossref], [Google Scholar], [Publisher]
[11]. M. Gyldenløve, F. Alinaghi, C. Zachariae, L. Skov, A. Egeberg, Combination therapy with apremilast and biologics for psoriasis: A systematic review, American Journal of Clinical Dermatology, 2022, 23, 605-613. [Crossref], [Google Scholar], [Publisher]
[12]. T. Saindane Manohar, C. Ge, Processes for the preparation of aminosulfone compounds, Celgene Corp, 2009. [Google Scholar], [Publisher]
[13]. G. Stavber, J. Cluzeau, Processes for the preparation of beta-aminosulfone compounds, Google Patents, 2018. [Google Scholar], [Publisher]
[14]. H. Narode, M. Gayke, G. Eppa, J.S. Yadav, A Review on Synthetic Advances toward the synthesis of apremilast, an anti-inflammatory drug, Organic Process Research & Development, 2021, 25, 1512-1523. [Crossref], [Google Scholar], [Publisher]
[15]. J.F. Syu, B. Gopula, J.H. Jian, W.S. Li, T.S. Kuo, P.Y. Wu, J.P. Henschke, M.C. Hsieh, M.K. Tsai, H.L. Wu, Asymmetric synthesis of β-Aryl β-imido sulfones using rhodium catalysts with chiral diene ligands: Synthesis of apremilast, Organic Letters, 2019, 21, 4614-4618. [Crossref], [Google Scholar], [Publisher]
[16]. V. Furlan, U. Bren, Insight into inhibitory mechanism of PDE4D by dietary polyphenols using molecular dynamics simulations and free energy calculations, Biomolecules, 2021, 11, 479. [Crossref], [Google Scholar], [Publisher]
[17]. C. Brideau, C. Van Staden, A. Styhler, I.W. Rodger, C.C. Chan, The effects of phosphodiesterase type 4 inhibitors on tumour necrosis factor-α and leukotriene B4 in a novel human whole blood assay, British Journal of Pharmacology, 1999, 126, 979-988. [Crossref], [Google Scholar], [Publisher]
[18]. S.L. Jin, S.L. Ding, S.C. Lin, Phosphodiesterase 4 and its inhibitors in inflammatory diseases, Chang Gung Medical Journal, 2012, 35, 197-210. [Crossref], [Google Scholar], [Publisher]
[19]. R.E. Petty et al., Textbook of pediatric rheumatology, 2016, 161-175. [Google Scholar], [Publisher]
[20]. J.B. Taylor, D.J. Triggle, Comprehensive medicinal chemistry II, Elsevier, Oxford, 2007, 969-985. [Google Scholar], [Publisher]
[21]. U. Food, OTEZLA®(Apremilast) prescribing information, 2017. [Publisher]
[22]. Q. Zhang, T. Durig, B. Blass, R. Fassihi, Development of an amorphous based sustained release system for apremilast a selective phosphodiesterase 4 (PDE4) inhibitor, International Journal of Pharmaceutics, 2022, 615, 121516. [Crossref], [Google Scholar], [Publisher]
[23]. I.S. Padda, R. Bhatt, M. Parmar, Apremilast, The National Center for Biotechnology Information, 2023. [Google Scholar], [Publisher]
[24]. G. Schett, V.S. Sloan, R.M. Stevens, P. Schafer, Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases, Therapeutic Advances in Musculoskeletal Disease, 2010, 2, 271-278. [Crossref], [Google Scholar], [Publisher]
[25]. Q.k. Lu, C. Fan, C.g. Xiang, B. Wu, H.m. Lu, C.l. Feng, X.q. Yang, H. Li, W. Tang, Inhibition of PDE4 by apremilast attenuates skin fibrosis through directly suppressing activation of M1 and T cells, Acta Pharmacologica Sinica, 2022, 43, 376-386. [Crossref], [Google Scholar], [Publisher]
[26]. P. Schafer, Apremilast mechanism of action and application to psoriasis and psoriatic arthritis, Biochemical Pharmacology, 2012, 83, 1583-1590. [Crossref], [Google Scholar], [Publisher]
[27]. H. Abdulrahim, S. Thistleton, A.O. Adebajo, T. Shaw, C. Edwards, A. Wells, Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis, Expert Opinion on Pharmacotherapy, 2015, 16, 1099-1108. [Crossref], [Google Scholar], [Publisher]
[28]. G.M.J.D. Keating, Apremilast: A review in psoriasis and psoriatic arthritis, Drugs, 2017, 77, 459-472. [Crossref], [Google Scholar], [Publisher]
[29]. A.S. Paller, Y. Hong, E.M. Becker, R. de Lucas, M. Paris, W. Zhang, Z. Zhang, C. Barcellona, P. Maes, L. Fiorillo, Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study, Journal of the American Academy of Dermatology, 2020, 82, 389-397. [Crossref], [Google Scholar], [Publisher]
[30]. K. Reich, M. Gooderham, A. Bewley, L. Green, J. Soung, R. Petric, J. Marcsisin, J. Cirulli, R. Chen, V. Piguet, Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study, Journal of the European Academy of Dermatology and Venereology, 2018, 32, 397-402. [Crossref], [Google Scholar], [Publisher]
[31]. A.B. Gottlieb, B. Strober, J.G. Krueger, P. Rohane, J.B. Zeldis, C.C. Hu, C. Kipnis, An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast, Current Medical Research and Opinion, 2008, 24, 1529-1538. [Crossref], [Google Scholar], [Publisher]
[32]. M. Hoffmann, G. Kumar, P. Schafer, D. Cedzik, L. Capone, K.L. Fong, Z. Gu, D. Heller, H. Feng, S. Surapaneni, O. Laskin, A. Wu, Disposition, metabolism and mass balance of [C]apremilast following oral administration, Xenobiotica, 2011, 41, 1063-1075. [Crossref], [Google Scholar], [Publisher]
[33]. S. Busa, A. Kavanaugh, Drug safety evaluation of apremilast for treating psoriatic arthritis, Expert Opinion on Drug Safety, 2015, 14, 979-985. [Crossref], [Google Scholar], [Publisher]
[34]. L. Bianchi, E. Del Duca, M. Romanelli, R. Saraceno, S. Chimenti, A. Chiricozzi, Toxicology, pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis, Expert Opinion on Drug Metabolism & Toxicology, 2016, 12, 1121-1128. [Crossref], [Google Scholar], [Publisher]
[35]. P.H. Schafer, P. Chen, L. Fang, A. Wang, R. Chopra, The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase III, randomized, placebo-controlled trial (PALACE 1), Journal of Immunology Research, 2015, 2015, 906349. [Crossref], [Google Scholar], [Publisher]
[36]. M. Cutolo, G.E. Myerson, R.M. Fleischmann, F. Lioté, F. Díaz-González, F. Van den Bosch, H. Marzo-Ortega, E. Feist, K. Shah, C. Hu, R.M. Stevens, A. Poder, A phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: Results of the PALACE 2 trial, The Journal of Rheumatology, 2016, 43, 1724-1734. [Crossref], [Google Scholar], [Publisher]
[37]. L. Bianchi, E. Del Duca, M. Romanelli, R. Saraceno, S. Chimenti, A. Chiricozzi, Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis, Expert Opinion on Drug Metabolism & Toxicology, 2016, 12, 1121-1128. [Crossref], [Google Scholar], [Publisher]
[38]. A. Chiricozzi, Pathogenic role of IL-17 in psoriasis and psoriatic arthritis, Actas Dermo-Sifiliograficas, 2014, 105 Suppl 1, 9-20. [Crossref], [Google Scholar], [Publisher]
[39]. A.K. Srivastava, T. Chand Yadav, H.K. Khera, P. Mishra, N. Raghuwanshi, V. Pruthi, R. Prasad, Insights into interplay of immunopathophysiological events and molecular mechanistic cascades in psoriasis and its associated comorbidities, Journal of Autoimmunity, 2021, 118, 102614. [Crossref], [Google Scholar], [Publisher]
[40]. S. Choudhary, N.S. Khan, R. Verma, P. Saxena, H. Singh, A.K. Jain, G. Thomas, D. Pradhan, N. Kumar, Exploring the molecular underpinning of psoriasis and its associated comorbidities through network approach: Cross talks of genes and pathways, 3 Biotech, 2023, 13, 130. [Crossref], [Google Scholar], [Publisher]
[41]. a) M. Quaranta, A.D. Burden, C.E.M. Griffiths, J. Worthington, J.N. Barker, R.C. Trembath, F. Capon, Differential contribution of CDKAL1 variants to psoriasis, Crohn's disease and type II diabetes, Genes & Immunity, 2009, 10, 654-658. [Crossref], [Google Scholar], [Publisher] b) P.A. Kalvanagh, Y.A. Kalvanagh, Comparison of exons 2 and 3 of DIRAS3 gene in mastectomies and lumpectomies women, Eurasian Journal of Science and Technology, 2023, 3, 147-157. [Crossref], [Publisher]
[42]. H. Cheng, Y. Li, X.B. Zuo, H.Y. Tang, X.F. Tang, J.P. Gao, Y.J. Sheng, X.Y. Yin, F.S. Zhou, C. Zhang, Identification of a missense variant in LNPEP that confers psoriasis risk, Journal of Investigative Dermatology, 2014, 134, 359-365. [Crossref], [Google Scholar], [Publisher]
[43]. a) S. Enhörning, M. Leosdottir, P. Wallström, B. Gullberg, G. Berglund, E. Wirfält, O.J.T.A.j.o.c.n. Melander, Relation between human vasopressin 1a gene variance, fat intake, and diabetes, The American Journal of Clinical Nutrition, 2009, 89, 400-406. [Crossref], [Google Scholar], [Publisher] b) M. Irajian, S.H. Ghaffari, Investigating the effect of diabetes on the incidence of carpal tunnel syndrome, Eurasian Journal of Science and Technology, 2024, 4, 66-75. [Crossref], [Publisher]
[44]. B.M. Patel, A. Mehta, Aldosterone and angiotensin: Role in diabetes and cardiovascular diseases, European Journal of Pharmacology, 2012, 697, 1-12. [Crossref], [Google Scholar], [Publisher]
[45]. T.-a. Nakada, J.A. Russell, H. Wellman, J.H. Boyd, E. Nakada, K.R. Thain, S.A. Thair, H. Hirasawa, S. Oda, K. Walley, Leucyl/cystinyl aminopeptidase gene variants in septic shock, CHEST, 2011, 139, 1042-1049. [Crossref], [Google Scholar], [Publisher]
[46]. S. Piaserico, G. Orlando, F. Messina, Psoriasis and cardiometabolic diseases: Shared genetic and molecular pathways, International Journal of Molecular Sciences, 2022, 23, 9063. [Crossref], [Google Scholar], [Publisher]
[47]. a) A.W. Armstrong, C.T. Harskamp, E.J. Armstrong, Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis, JAMA Dermatology, 2013, 149, 84-91. [Crossref], [Google Scholar], [Publisher] b) F. Haghi, S. Ebrahimi, M. Afzali, H.M. Bidhendi, Investigating the relationship between diabetes and the consequences of kidney transplantation, Advanced Journal of Chemistry, Section B: Natural Products and Medical Chemistry, 2023, 5, 108-114. [Crossref], [Publisher]
[48]. J. Shapiro, A.D. Cohen, M. David, E. Hodak, G. Chodik, A. Viner, E. Kremer, A. Heymann, The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study, Journal of the American Academy of Dermatology, 2007, 56, 629-634. [Crossref], [Google Scholar], [Publisher]
[49]. a) A. Cohen, J. Dreiher, Y. Shapiro, L. Vidavsky, D. Vardy, B. Davidovici, J. Meyerovitch, Psoriasis and diabetes: A population-based cross-sectional study, JEADV, 2008, 22, 585-589. [Crossref], [Google Scholar], [Publisher] b) S. Charsouei, A.R. Lotfi, Symptoms and complications of nervous system in patients with mucormycosis: A systematic review, Advanced Journal of Chemistry, Section B: Natural Products and Medical Chemistry, 2022, 4, 261-270. [Crossref], [Publisher]
[50]. Y.B. Brauchli, S.S. Jick, C.R. Meier, Psoriasis and the risk of incident diabetes mellitus: A population-based study, British Journal of Dermatology, 2008, 159, 1331-1337. [Crossref], [Google Scholar], [Publisher]
[51]. A. Di Cesare, F. Ricceri, E. Rosi, M.T. Fastame, F. Prignano, Therapy of PsO in special subsets of patients, Biomedicines, 2022, 10, 2879. [Crossref], [Google Scholar], [Publisher]
[52]. J. Takeshita, S. Grewal, S.M. Langan, N.N. Mehta, A. Ogdie, A.S. Van Voorhees, J. Gelfand, Psoriasis and comorbid diseases: Epidemiology, Journal of the American Academy of Dermatology, 2017, 76, 377-390. [Crossref], [Google Scholar], [Publisher]
[53]. M. Mamizadeh, Z. Tardeh, M. Azami, The association between psoriasis and diabetes mellitus: A systematic review and meta-analysis, Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 2019, 13, 1405-1412. [Crossref], [Google Scholar], [Publisher]
[54]. M.T. Wan, D.B. Shin, R.A. Hubbard, M.H. Noe, N.N. Mehta, J.M. Gelfand, Psoriasis and the risk of diabetes: A prospective population-based cohort study, Journal of the American Academy of Dermatology, 2018, 78, 315-322.e311. [Crossref], [Google Scholar], [Publisher]
[55]. E.A. Chandran, V. M., N. Mathew Valooran, A. Kumar R., A Recent update on pyridine derivatives as a potential lead for diabetes mellitus, Journal of Chemical Reviews, 2023, 5, 159-182. [Crossref], [Publisher]
[56]. R. Abramczyk, J.N. Queller, A.W. Rachfal, S.S. Schwartz, Diabetes and psoriasis: Different sides of the same prism, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, 13, 3571-3577. [Google Scholar], [Publisher]
[57]. K. Yamanaka, O. Yamamoto, T. Honda, Pathophysiology of psoriasis: A review, The Journal of Dermatology, 2021, 48, 722-731. [Crossref], [Google Scholar], [Publisher]
[58]. a) S.S. Schwartz, S. Epstein, B.E. Corkey, S.F.A. Grant, J.R. Gavin Iii, R.B. Aguilar, M.E. Herman, A unified pathophysiological construct of diabetes and its complications, Trends in Endocrinology and Metabolism: TEM, 2017, 28, 645-655. [Crossref], [Google Scholar], [Publisher] b) K. Aminu, A. Uzairu, S. Abechi, G. Adamu, A. Umar, A search for novel antidiabetic agents using ligand-based drug design and molecular docking studies employing human intestinal maltase-glucoamylase as model enzyme, Advanced Journal of Chemistry, Section A, 2023, 6, 155-171. [Crossref], [Google Scholar], [Publisher]
[59]. H.H. Ayvaz, K.H. Öztürk, M.A. Seyirci, E. Atay, S. Korkmaz, İ. Erturan, M. Yıldırım, The role of EREG, PTPN1, and SERPINB7 genes in the pathogenesis of psoriasis: May SERPINB7 be protective and a marker of severity for psoriasis?, Dermatology Practical & Conceptual, 2023, 13, e2023085. [Crossref], [Google Scholar], [Publisher]
[60]. M.X. Zhang, B.Y. Zheng, H.X. Chen, C.W. Chien, Clinical effects of antidiabetic drugs on psoriasis: The perspective of evidence-based medicine, World Journal of Diabetes, 2021, 12, 1141-1145. [Crossref], [Google Scholar], [Publisher]
[61]. C. Wu, S. Rajagopalan, Phosphodiesterase-4 inhibition as a therapeutic strategy for metabolic disorders, Obesity Reviews, 2016, 17, 429-441. [Crossref], [Google Scholar], [Publisher]
[62]. J.N. Mayba, M.J. Gooderham, Real-world experience with apremilast in treating psoriasis, Journal of Cutaneous Medicine and Surgery, 2017, 21, 145-151. [Crossref], [Google Scholar], [Publisher]
[63]. R. Persson, M. Cordey, M. Paris, S. Jick, Safety of apremilast in patients with psoriasis and psoriatic arthritis: Findings from the UK clinical practice research datalink, Drug Safety, 2022, 45, 1403-1411. [Crossref], [Google Scholar], [Publisher]
[64]. S. Mazzilli, C. Lanna, C. Chiaramonte, G.M. Cesaroni, A. Zangrilli, V. Palumbo, T. Cosio, A. Dattola, R. Gaziano, M. Galluzzo, M.S. Chimenti, P. Gisondi, L. Bianchi, E. Campione, Real life experience of apremilast in psoriasis and arthritis psoriatic patients: Preliminary results on metabolic biomarkers, The Journal of Dermatology, 2020, 47, 578-582. [Crossref], [Google Scholar], [Publisher]
[65]. M. Adiguna, M. Wardhana, F. Nathania, Positive correlation between psoriasis vulgaris severity degree with HbA1C level, Bali Dermatology and Venereology Journal, 2019, 1. [Crossref], [Google Scholar], [Publisher]
[66]. K. Ikumi, K. Torii, Y. Sagawa, Y. Kanayama, A. Nakada, H. Nishihara, A. Morita, Phosphodiesterase 4 inhibitor apremilast improves insulin resistance in psoriasis patients, The Journal of Dermatology, 2022, 49, e125-e126. [Crossref], [Google Scholar], [Publisher]
[67]. M. Ogoshi, T. Horikawa, Rapid improvement of psoriasis in diabetes subsequent to glucose lowering, International Journal of Dermatology, 2014, 53, e106-e107. [Crossref], [Google Scholar], [Publisher]
[68]. J. Crowley, D. Thaçi, P. Joly, K. Peris, K.A. Papp, J. Goncalves, R.M. Day, R. Chen, K. Shah, C. Ferrándiz, J.C. Cather, Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2), Journal of the American Academy of Dermatology, 2017, 77, 310-317.e311. [Crossref], [Google Scholar], [Publisher]
[69]. L. Stein Gold, K. Papp, D. Pariser, L. Green, N. Bhatia, H. Sofen, L. Albrecht, M. Gooderham, M. Chen, M. Paris, Y. Wang, K. Callis Duffin, Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial, Journal of the American Academy of Dermatology, 2022, 86, 77-85. [Crossref], [Google Scholar], [Publisher]
[70]. L.F. Stein Gold, J. Bagel, S.K. Tyring, H.C.-h. Hong, L. Pavlovsky, R. Vender, A. Pinter, A. Reich, L. Drogaris, T. Wu, M. Patel, A.M. Soliman, H. Photowala, V. Stakias, S. Richter, K.A. Papp, Comparison of risankizumab and apremilast for the treatment of adult patients with moderate plaque psoriasis eligible for systemic therapy: results from a randomised, open-label, assessor-blinded phase IV (IMMpulse) study, British Journal of Dermatology, 2023, 189, 540-552. [Crossref], [Google Scholar], [Publisher]
[71] Y. Liu, S. Zhou, Y. Wan, A. Wu, M. Palmisano, The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers, British Journal of Clinical Pharmacology, 2014, 78, 1050-1057. [Crossref], [Google Scholar], [Publisher]
[72] R. Fischer-Betz, M. Østensen, Biologics and small molecules in the management of psoriatic arthritis: Reproduction related issues in female and male patients, Expert Review of Clinical Pharmacology, 2021, 14, 979-989. [Crossref], [Google Scholar], [Publisher]
)